ARGX
- argenx SE
()
Overview
Company Summary
argenx SE is a biotechnology company that specializes in the development of innovative antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Through its proprietary antibody discovery platform, the company aims to create novel therapeutic options that address unmet medical needs.
argenx focuses on the discovery and development of antibodies that target the immune system. By modulating the immune response, these antibodies can potentially counteract the underlying causes of various diseases.
The company's flagship product is efgartigimod, a potential treatment for a rare autoimmune disorder called generalized myasthenia gravis (gMG). Efgartigimod is an antibody fragment designed to target and neutralize disease-causing antibodies, thereby reducing the pathogenic immune response. argenx has also initiated clinical trials to evaluate efgartigimod in other autoimmune diseases such as immune thrombocytopenia (ITP) and chronic inflammatory demyelinating polyneuropathy (CIDP).
In addition to efgartigimod, argenx has an extensive pipeline of other potential antibody-based therapies at various stages of development. The company collaborates with strategic partners and utilizes its innovative discovery platform to create a diverse portfolio of therapeutic candidates.
Overall, argenx is dedicated to harnessing the power of antibodies to develop transformative medicines that offer new treatment options for patients suffering from severe autoimmune diseases and cancer.